Search

Author/Creator Rubin, Daniel B

2. Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy. Issue 11 (30th November 2022)

Authors:
Amidi, Yalda; Eckhardt, Christine A; Quadri, Syed A; Malik, Preeti; Firme, Marcos Santana; Jones, Daniel K; Jain, Aayushee; Danish, Husain H; Rubin, Daniel B; Jacobson, Caron A; Cash, Sydney S; Lee, Jong Woo; Dietrich, Jorg; Westover, M Brandon
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 10:Issue 11(2022)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®). (2nd December 2020)

Authors:
Naseer, Shabnam; Weinstein, Edward A; Rubin, Daniel B; Suvarna, Kalavati; Wei, Xiaohui; Higgins, Karen; Goodwin, Avery; Jang, Seong H; Iarikov, Dmitri; Farley, John; Nambiar, Sumathi
Journal:
Clinical infectious diseases
Issue:
Volume 72:Number 12(2021)
Page Start:
e1103
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗